CUREVAC NV (1CVAC.MI) Stock Fundamental Analysis
Europe - BIT:1CVAC - NL0015436031 - Common Stock
4.608 EUR
-0.07 (-1.58%)
Taking everything into account, 1CVAC scores 6 out of 10 in our fundamental rating. 1CVAC was compared to 73 industry peers in the Biotechnology industry. 1CVAC has an excellent financial health rating, but there are some minor concerns on its profitability. 1CVAC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1CVAC was profitable.
1CVAC had a positive operating cash flow in the past year.
1CVAC had negative earnings in 4 of the past 5 years.
In multiple years 1CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
1CVAC's Return On Assets of 28.11% is amongst the best of the industry. 1CVAC outperforms 91.36% of its industry peers.
The Return On Equity of 1CVAC (33.02%) is better than 93.83% of its industry peers.
With an excellent Return On Invested Capital value of 28.35%, 1CVAC belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1CVAC's Profit Margin of 37.93% is amongst the best of the industry. 1CVAC outperforms 88.89% of its industry peers.
With an excellent Operating Margin value of 40.58%, 1CVAC belongs to the best of the industry, outperforming 93.83% of the companies in the same industry.
With an excellent Gross Margin value of 94.81%, 1CVAC belongs to the best of the industry, outperforming 87.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1CVAC is creating value.
The number of shares outstanding for 1CVAC remains at a similar level compared to 1 year ago.
1CVAC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1CVAC has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 9.56 indicates that 1CVAC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.56, 1CVAC belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
The Debt to FCF ratio of 1CVAC is 0.18, which is an excellent value as it means it would take 1CVAC, only 0.18 years of fcf income to pay off all of its debts.
1CVAC's Debt to FCF ratio of 0.18 is amongst the best of the industry. 1CVAC outperforms 91.36% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that 1CVAC is not too dependend on debt financing.
1CVAC has a Debt to Equity ratio of 0.05. This is in the better half of the industry: 1CVAC outperforms 65.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.56 |
ROIC/WACC3.93
WACC7.22%
2.3 Liquidity
1CVAC has a Current Ratio of 6.17. This indicates that 1CVAC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.17, 1CVAC belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
A Quick Ratio of 6.16 indicates that 1CVAC has no problem at all paying its short term obligations.
1CVAC has a better Quick ratio (6.16) than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
1CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
Based on estimates for the next years, 1CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
Based on estimates for the next years, 1CVAC will show a very negative growth in Revenue. The Revenue will decrease by -11.22% on average per year.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.30, which indicates a rather cheap valuation of 1CVAC.
1CVAC's Price/Earnings ratio is rather cheap when compared to the industry. 1CVAC is cheaper than 92.59% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.89. 1CVAC is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for 1CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.3 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1CVAC is valued cheaper than 93.83% of the companies in the same industry.
1CVAC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1CVAC is cheaper than 93.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.29 | ||
| EV/EBITDA | 3 |
4.3 Compensation for Growth
1CVAC has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as 1CVAC's earnings are expected to decrease with -31.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
5. Dividend
5.1 Amount
No dividends for 1CVAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1CVAC (10/6/2025, 7:00:00 PM)
4.608
-0.07 (-1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.04B
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.16 (-9.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)79.51%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)383.16%
Revenue beat(8)4
Avg Revenue beat(8)55.15%
Revenue beat(12)4
Avg Revenue beat(12)22.54%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.37%
PT rev (3m)-9.1%
EPS NQ rev (1m)-275%
EPS NQ rev (3m)-1786.66%
EPS NY rev (1m)0%
EPS NY rev (3m)11.05%
Revenue NQ rev (1m)220.62%
Revenue NQ rev (3m)140.45%
Revenue NY rev (1m)-14.05%
Revenue NY rev (3m)-14.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.3 | ||
| Fwd PE | N/A | ||
| P/S | 2.03 | ||
| P/FCF | 5.29 | ||
| P/OCF | 5.08 | ||
| P/B | 1.77 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 3 |
EPS(TTM)0.87
EY18.88%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY18.9%
OCF(TTM)0.91
OCFY19.67%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.56 |
F-Score9
WACC7.22%
ROIC/WACC3.93
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5YN/A
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 1CVAC.MI FAQ
What is the ChartMill fundamental rating of CUREVAC NV (1CVAC.MI) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1CVAC.MI.
What is the valuation status of CUREVAC NV (1CVAC.MI) stock?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (1CVAC.MI). This can be considered as Fairly Valued.
What is the profitability of 1CVAC stock?
CUREVAC NV (1CVAC.MI) has a profitability rating of 6 / 10.
Can you provide the financial health for 1CVAC stock?
The financial health rating of CUREVAC NV (1CVAC.MI) is 9 / 10.